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•
The full guidance (this document).
• A quick reference guide for healthcare professionals.
• Information for people with primary (heterozygous-familial and nonfamilial) hypercholesterolaemia and their carers ('Understanding NICE guidance').
• Details of all the evidence that was looked at and other background information.
For printed copies of the quick reference guide or 'Understanding NICE guidance', phone the NHS Response Line on 0870 1555 455 and quote:
• N1402 (quick reference guide) • N1403 ('Understanding NICE guidance').
This guidance is written in the following context
This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. The guidance does not, however, override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Guidance
This guidance should be read in conjunction with NICE guidance on the initiation of statin therapy (NICE technology appraisal guidance 94). NICE has published clinical guidelines on the management of blood pressure and blood lipids in people with type 2 diabetes (Inherited clinical guideline H) and secondary prevention for patients following a myocardial infarction (NICE clinical guideline 48). The following clinical guidelines are under development: lipid modification; familial hypercholesterolaemia; type 2 diabetes (update).
This guidance should be read in the context of the relevant clinical guideline, when available.
Ezetimibe monotherapy is recommended as an option for the treatment of adults with primary (heterozygous-familial or non-familial)
hypercholesterolaemia who would otherwise be initiated on statin therapy (as per NICE guidance TA 94 in adults with non-familial hypercholesterolaemia) but who are unable to do so because of contraindications to initial statin therapy.
1.2
Ezetimibe monotherapy is recommended as an option for the treatment of adults with primary (heterozygous-familial or non-familial) hypercholesterolaemia who are intolerant to statin therapy (as defined in section 1.6).
1.3
Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with primary (heterozygous-familial or nonfamilial) hypercholesterolaemia who have been initiated on statin therapy (as per NICE guidance TA 94 in adults with non-familial hypercholesterolaemia) when:
• serum total or low-density lipoprotein (LDL) cholesterol concentration is not appropriately controlled (as defined in section 1.5) either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy (as defined in section 1.6) and
• consideration is being given to changing from initial statin therapy to an alternative statin.
1.4
When the decision has been made to treat with ezetimibe coadministered with a statin, ezetimibe should be prescribed on the basis of lowest acquisition cost.
1.5
For the purposes of this guidance, appropriate control of cholesterol concentrations should be based on individualised risk assessment in accordance with national guidance on the management of cardiovascular disease for the relevant populations.
1.6
For the purposes of this guidance, intolerance to initial statin therapy should be defined as the presence of clinically significant adverse effects from statin therapy that are considered to represent an unacceptable risk to the patient or that may result in compliance with therapy being compromised. Adverse effects include evidence of new-onset muscle pain (often associated with levels of muscle enzymes in the blood indicative of muscle damage), significant gastrointestinal disturbance or alterations of liver function tests. 
Evidence and interpretation
The Appraisal Committee (appendix A) considered evidence from a number of sources (appendix B). 
Clinical effectiveness

Adverse events
4.1.10 Adverse events reported in each of the included studies were summarised by the Assessment Group. Meta-analyses were considered inappropriate because of insufficient data and low occurrences of adverse events.
4.1.11 Therapy with ezetimibe coadministered with a statin was found to have a similar adverse event profile to that of statin therapy alone. It was found that treatment-related adverse events ranged from 14% to 23% in the ezetimibe plus statin arm and from 13% to 27% in the statin-only arm. The number of people that discontinued treatment because of treatment-related adverse events was similar across both treatment groups (1% to 6% in the ezetimibe plus statin arm and 1% to 7% in the statin-only arm). Ezetimibe monotherapy was found to have a similar adverse event profile to placebo. The most commonly reported adverse events were musculoskeletal disorders (2-5%) and upper respiratory infections (7-11%). It was found that treatment-related adverse events ranged from 9% to 18% in the ezetimibe monotherapy arm and from 9% to 24% in the placebo arm. • Scenario 1 -ezetimibe coadministered with current statin therapy versus current statin therapy titrated to the next dose.
Cost effectiveness
• Scenario 2 -ezetimibe monotherapy versus no treatment.
• Scenario 3 -ezetimibe coadministered with non-proprietary simvastatin versus atorvastatin.
• Scenario 4 -ezetimibe coadministered with current statin therapy versus current statin therapy alone.
• Scenario 5 -ezetimibe coadministered with rosuvastatin versus rosuvastatin monotherapy. 
4.2.10
The Assessment Group reported that there is a lack of published evidence on costs for some of the health states modelled, and assumptions based on expert opinion were used where published evidence was not available. Expert opinions were used to inform the levels and types of monitoring required, and published UK costs were applied to these estimates. Drug costs were taken from the BNF 53rd edition. The cost of current statin therapy for scenarios 1 and 4 is a weighted cost based on published data on prescribing rates in England in 2005. The costs of treatment-related adverse events were not included. Where necessary, costs used in the economic analysis were adjusted to 2006 prices. The analysis was conducted from a UK NHS perspective, and a discount rate of 3.5% on costs and benefits was applied.
4.2.11
Health-related utility data were obtained from published studies supported by clinical advice and were adjusted for age using data from a large UKpopulation-based survey using the EQ-5D. No reduction in utility for adverse effects of treatment was modelled. 4.2.13 For scenario 1, the incremental costs per QALY gained ranged from £24,000
Results
to £43,000. The results were generally higher in women, older age groups and people without CVD. The incremental costs per QALY gained were between £24,000 and £31,000 for people aged 45 to 65 years, and between £29,000 and £43,000 for people aged 75 years.
4.2.14 For scenario 2, the incremental costs per QALY gained ranged from £24,000
to £42,000 and were generally higher in women, older age groups and people without CVD. The incremental costs per QALY gained were between £24,000 and £30,000 for people aged 45 to 65 years, and between £33,000 and £42,000 for people aged 75 years.
4.2.15
For scenario 3, the incremental costs per QALY gained ranged from £1500 to £4600, with only small variations between different groups.
4.2.16
For scenarios 4 and 5, the incremental costs per QALY gained ranged from £19,000 to £33,000. The results were generally higher in women, older age groups and people without CVD. The incremental costs per QALY gained were between £19,000 and £24,000 for people aged 45 to 65 years, and between £26,000 and £33,000 for people aged 75 years. 5.3 NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website (www.nice.org.uk/TA132).
Consideration of the evidence
Implementation
• Audit criteria to monitor local practice.
• A costing statement explaining the resource impact of this guidance.
6
Recommendations for further research Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal. 
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